We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Harvard Bioscience (HBIO) Stock Outpacing Its Computer and Technology Peers This Year?
Read MoreHide Full Article
The Computer and Technology group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Harvard Bioscience (HBIO - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Computer and Technology sector should help us answer this question.
Harvard Bioscience is a member of our Computer and Technology group, which includes 627 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HBIO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for HBIO's full-year earnings has moved 20% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, HBIO has gained about 96.97% so far this year. Meanwhile, stocks in the Computer and Technology group have gained about 9.11% on average. This means that Harvard Bioscience is outperforming the sector as a whole this year.
To break things down more, HBIO belongs to the Instruments - Scientific industry, a group that includes 6 individual companies and currently sits at #223 in the Zacks Industry Rank. On average, this group has lost an average of 4.09% so far this year, meaning that HBIO is performing better in terms of year-to-date returns.
Investors with an interest in Computer and Technology stocks should continue to track HBIO. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Harvard Bioscience (HBIO) Stock Outpacing Its Computer and Technology Peers This Year?
The Computer and Technology group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Harvard Bioscience (HBIO - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Computer and Technology sector should help us answer this question.
Harvard Bioscience is a member of our Computer and Technology group, which includes 627 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HBIO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for HBIO's full-year earnings has moved 20% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, HBIO has gained about 96.97% so far this year. Meanwhile, stocks in the Computer and Technology group have gained about 9.11% on average. This means that Harvard Bioscience is outperforming the sector as a whole this year.
To break things down more, HBIO belongs to the Instruments - Scientific industry, a group that includes 6 individual companies and currently sits at #223 in the Zacks Industry Rank. On average, this group has lost an average of 4.09% so far this year, meaning that HBIO is performing better in terms of year-to-date returns.
Investors with an interest in Computer and Technology stocks should continue to track HBIO. The stock will be looking to continue its solid performance.